![]() Up to one hundred and fifty-five subjects will be enrolled into one of thirteen cohorts (10 micrograms, 25 mcg, 50 mcg, 100 mcg, and 250 mcg). ![]() Enrollment will occur at up to 3 domestic clinical research sites. ![]() mRNA-1273 is a novel lipid nanoparticle (LNP)-encapsulated mRNA-based vaccine that encodes for a full-length, prefusion stabilized spike (S) protein of SARS-CoV-2. This clinical trial is designed to assess the safety, reactogenicity and immunogenicity of mRNA-1273 manufactured by ModernaTX, Inc. This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria. Why Should I Register and Submit Results?. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |